Holen Sie sich die Stockscreener-App
17.58
8.20%
-1.57
Handel nachbörslich:
17.69
0.11
+0.63%
Schlusskurs vom Vortag:
$19.15
Offen:
$19.06
24-Stunden-Volumen:
2.21M
Relative Volume:
1.53
Marktkapitalisierung:
$2.07B
Einnahmen:
$4.02M
Nettoeinkommen (Verlust:
$-224.59M
KGV:
-7.3881
EPS:
-2.3795
Netto-Cashflow:
$-205.52M
1W Leistung:
-8.96%
1M Leistung:
-28.74%
6M Leistung:
-22.28%
1J Leistung:
+23.37%
1-Tages-Spanne:
$17.43
$19.16
1-Wochen-Bereich:
$17.43
$19.73
52-Wochen-Spanne:
$13.53
$30.06
Immunome Inc Stock (IMNM) Company Profile
Firmenname
Immunome Inc
Sektor
Branche
Telefon
610-321-3700
Adresse
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
17.58 | 2.07B | 4.02M | -224.59M | -205.52M | -2.3795 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-01 | Eingeleitet | Stifel | Hold |
| 2026-09-21 | Eingeleitet | Alliance Global Partners | Buy |
| 2026-05-28 | Eingeleitet | Barclays | Overweight |
| 2026-02-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-12-01 | Eingeleitet | Truist | Buy |
| 2025-09-22 | Eingeleitet | Goldman | Buy |
| 2025-09-05 | Eingeleitet | Craig Hallum | Buy |
| 2025-04-02 | Eingeleitet | Lake Street | Buy |
| 2024-11-08 | Eingeleitet | Stephens | Overweight |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-04-30 | Eingeleitet | JP Morgan | Overweight |
| 2024-04-15 | Eingeleitet | Guggenheim | Buy |
| 2024-01-29 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-19 | Eingeleitet | Wedbush | Outperform |
| 2021-10-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Immunome Inc Aktie (IMNM) Neueste Nachrichten
Price-Driven Insight from (IMNM) for Rule-Based Strategy - Stock Traders Daily
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Immunome stock holds at Stifel as Bristol deal cleans up license - Investing.com
ImmunomeEnters Amendment No. 4 To License Agreement With Bristol-Myers Squibb Company On Oct 2, 2026 - TradingView
Immunome stock gets FDA clearance for fifth clinical program - AD HOC NEWS
Immunome, Inc. (IMNM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Immunome (IMNM) Is Down 6.5% After FDA Clears IND For Novel ADC IM-1340 Trial – Has The Bull Case Changed? - Yahoo Finance
IMNM Initiated Coverage by Stifel -- Rated Hold with PT at $24.0 - gurufocus.com
Stifel Initiates Immunome at Hold With $24 Price Target - Yahoo Finance
Immunome (IMNM) Stock Looks Near Fair Value As Its 186% Run Continues - Yahoo Finance
Immunome gains FDA IND clearance for IM‑1340 solid tumour study - Mugglehead Investment Magazine
Stifel initiates Immunome stock coverage with Hold rating at $24 By Investing.com - Investing.com Nigeria
Stifel initiates Immunome stock coverage with Hold rating at $24 - Investing.com
Stifel initiates Immunome stock coverage with Hold rating at $24 By Investing.com - Investing.com South Africa
Immunome (IMNM) Gains FDA IND Clearance for IM-1340 Targeting Ad - gurufocus.com
Immunome receives FDA clearance for IM-1340 solid tumor trial - Investing.com
Immunome receives FDA clearance for IM-1340 solid tumor trial By Investing.com - Investing.com South Africa
Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors - Business Wire
(IMNM) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
A. G. P. Initiates Immunome(IMNM.US) With Buy Rating, Announces Target Price $32 - Moomoo
IMNM Initiates Coverage On Alliance Global Partners -- Rating Se - GuruFocus
Immunome (Nasdaq:IMNM)Stock Analysis - Simply Wall Street
Immunome Stock Price Forecast. Should You Buy IMNM? - StockInvest.us
Immunome, Inc. (IMNM) Stock Analysis: Exploring a 51.72% Potential Upside in Biotechnology - DirectorsTalk Interviews
Immunome CSO Higgins Jack Executes 18,000 Options at $1.35, Sells and Gifts Shares (NASDAQ: IMNM) - Kalkine Media
Immunome Inc. (IMNM) Edges Up 2.51% to $24.55 as Buyers Hold Above Key SupportPCR Spike - careplusvn.com
Liquidity Mapping Around (IMNM) Price Events - Stock Traders Daily
Planned sale of 13,200 Immunome (NASDAQ: IMNM) shares disclosed in Rule 144 notice - Stock Titan
IMNM Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
GOOG: Alphabet IncOrdinary SharesClass C Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Immunome, Inc. Revenue Breakdown – NASDAQ:IMNM - TradingView
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
Immunome (NASDAQ:IMNM) Is In A Good Position To Deliver On Growth Plans - Moomoo
(IMNM) Volatility Zones as Tactical Triggers - Stock Traders Daily
Immunome (IMNM) Reports A Wider Loss, Is The Premium Valuation Justified? - Sahm
Immunome (IMNM) Update: Closes 0.98% Lower at $28.24 at the Close; Chart Watch: Traders Can Monitor the $26.83-$29.65 Range in the Current UpdateCommon Gap - siam.in
Immunome (IMNM) Update: Closes 0.98% Lower at $28.24 at the Close; Chart Watch: Traders Can Monitor the $26.83-$29.65 Range in the Current UpdateSmart Beta Flow - vinanet.vn
Immunome (IMNM) Results Review: EPS Clears the Reported Estimate for the Current Session; Closing Move - dars.gov.et
Should Immunome’s (IMNM) Rising Losses and ESOP Shelf Offering Require Action From Investors? - Sahm
Should Immunome’s (IMNM) Rising Losses and ESOP Shelf Offering Require Action From Investors? - simplywall.st
Enterprise value to revenue forward of Immunome, Inc. – NASDAQ:IMNM - TradingView
Bank of America Corp DE Boosts Stake in Immunome, Inc. $IMNM - MarketBeat
Enterprise value to EBIT forward of Immunome, Inc. – NASDAQ:IMNM - TradingView
Immunome (NASDAQ:IMNM) Sets New 12-Month HighShould You Buy? - MarketBeat
Immunome (IMNM) Faces A Valuation Test Following Earnings And Shelf Registration - Sahm
Immunome, Inc. (NASDAQ:IMNM) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
IMNM Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost Discipline at Pre-Revenue Oncology BiotechBuyback Announcement Report - vinanet.vn
Is Immunome’s (IMNM) Russell Exit Quietly Recasting Its Shareholder Base And Liquidity Story? - Sahm
Immunome director Isaac Barchas sells $940,453 in common stock - Investing.com
Finanzdaten der Immunome Inc-Aktie (IMNM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immunome Inc-Aktie (IMNM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Higgins Jack | Chief Scientific Officer |
Sep 11 '26 |
Sale |
25.32 |
13,200 |
334,224 |
65,050 |
| Higgins Jack | Officer |
Sep 11 '26 |
Proposed Sale |
25.32 |
13,200 |
334,224 |
0 |
| Barchas Isaac | Director |
Aug 12 '26 |
Proposed Sale |
27.25 |
11,048 |
301,058 |
0 |
| Barchas Isaac | Director |
Aug 12 '26 |
Sale |
27.25 |
11,048 |
301,058 |
92,211 |
| Barchas Isaac | Director |
Aug 11 '26 |
Sale |
26.23 |
62,291 |
1,633,893 |
0 |
| Barchas Isaac | Director |
Aug 10 '26 |
Sale |
26.07 |
10,125 |
263,959 |
62,291 |
| Barchas Isaac | Director |
Aug 07 '26 |
Sale |
26.06 |
15,248 |
397,363 |
72,416 |
| Barchas Isaac | Director |
Aug 06 '26 |
Sale |
26.06 |
20,840 |
543,090 |
87,664 |
| ABHMC II, LLC | Shareholder |
Aug 06 '26 |
Proposed Sale |
25.52 |
108,504 |
2,769,022 |
0 |
| Horn Kinney | CHIEF BUSINESS OFFICER |
Aug 04 '26 |
Sale |
25.09 |
90,616 |
2,273,555 |
0 |
0.44%
1.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):